Champions Oncology (CSBR) Change in Accured Expenses (2010 - 2026)
Champions Oncology's (CSBR) quarterly Change in Accured Expenses came in at $83000.0 in Q3 2026, up 110.99% year-over-year from $39337.7 in Q3 2025, and up 111.02% on a QoQ basis from -$753000.0 in Q2 2026.
Powered by 
Analysis
Champions Oncology (CSBR) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Champions Oncology (CSBR) has 17 years of Change in Accured Expenses data on file, last reported at $83000.0 in Q3 2026.
- On a quarterly basis, Change in Accured Expenses rose 110.99% year-over-year to $83000.0 in Q3 2026; TTM through Jul 2026 was $875000.0, a 394.61% increase from a year earlier, with the FY2026 full-year figure at $37000.0, down 90.63% from the prior year.
- Change in Accured Expenses for Q3 2026 stood at $83000.0, up from -$753000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.2 million in Q1 2026 and bottomed at -$755000.0 in Q3 2025.
- Historically, Change in Accured Expenses has averaged $40210.5 across 5 years, with a median of $83000.0 in 2026.
- The widest annual swing landed in 2025, when Change in Accured Expenses tumbled 1098.41%; it then surged 3515.62% in 2026.
- Year by year, Change in Accured Expenses stood at -$287000.0 in 2022, then surged by 76.66% to -$67000.0 in 2023, then soared by 304.48% to $137000.0 in 2024, then surged by 183.21% to $388000.0 in 2025, then tumbled by 78.61% to $83000.0 in 2026.
- Per Business Quant data, the three most recent Change in Accured Expenses figures were $83000.0 in Q3 2026, -$753000.0 in Q2 2026, and $1.2 million in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | - |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | 45.02 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | - |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | 18.90 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | 25.10 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | 3.94 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | 83,000.00 |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | - |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | -243,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 31, 2026 | 83,000.00 |
| Apr 30, 2026 | -753,000.00 |
| Jan 31, 2026 | 1.16 Mn |
| Oct 31, 2025 | 388,000.00 |
| Jul 31, 2025 | -755,000.00 |
| Apr 30, 2025 | 289,000.00 |
| Jan 31, 2025 | 32,000.00 |
| Oct 31, 2024 | 137,000.00 |
| Jul 31, 2024 | -63,000.00 |
| Apr 30, 2024 | -269,000.00 |
| Jan 31, 2024 | 405,000.00 |
| Oct 31, 2023 | -67,000.00 |
| Jul 31, 2023 | -178,000.00 |
| Apr 30, 2023 | 238,000.00 |
| Jan 31, 2023 | 360,000.00 |
| Oct 31, 2022 | -287,000.00 |
| Jul 31, 2022 | -456,000.00 |
| Apr 30, 2022 | 388,000.00 |
| Jan 31, 2022 | 115,000.00 |
| Oct 31, 2021 | -70,000.00 |